Preclinical experiments and an ongoing phase 1 trial suggest that RES-010 may complement and enhance the efficacy of ...

Weight-loss medications reduced body weight in children and teens, but the sample size was too small to make conclusions ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...

Compared with usual care, GLP-1 receptor agonists tirzepatide and semaglutide may be cost-effective options for patients with ...

This multicenter, prospective observational study is published in Frontiers in Clinical Diabetes and Healthcare. “Pre-treatment assessment of eating behavior patterns may help predict who will benefit ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...

Eli Lilly LLY announced positive top-line data from a late-stage head-to-head study evaluating its once-daily small molecule (non-peptide) oral GLP-1 receptor agonist, orforglipron, compared to Novo ...

Paris, France, Thursday, 18 September 2025) Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower ...

Tirzepatide was associated with significant declines in HbA1c and BMI for children and adolescents with type 2 diabetes, according to data from the SURPASS-PEDS trial. Tamara S. Hannon, MD, professor ...

Learn how Orforglipron oral GLP-1 pill treats obesity and type 2 diabetes, supporting weight loss and glucose control. Discover benefits today!

That means shifting cooking methods, moderating portions, and tackling obesogenic environments like 24-hour eateries and ...